Drug Type Small molecule drug |
Synonyms Molindone, Molindone XR, Molindone hydrochloride (USP) + [7] |
Target |
Mechanism D2 receptor antagonists(Dopamine D2 receptor antagonists) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization |
Drug Highest PhaseApproved |
First Approval Date US (18 Jan 1974), |
Regulation- |
Molecular FormulaC16H24N2O2 |
InChIKeyKLPWJLBORRMFGK-UHFFFAOYSA-N |
CAS Registry7416-34-4 |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
D00796 | Molindone hydrochloride |
Indication | Country/Location | Organization | Date |
---|---|---|---|
Schizophrenia | US | 20 Mar 2015 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Attention Deficit Disorder With Hyperactivity | Preclinical | US | 16 Feb 2016 |
Not Applicable | 119 | (rqqqmjvgkw) = epfxauyzdk dgmjdkzatp (llavojvxzw ) | Negative | 01 Nov 2008 | |||
(rqqqmjvgkw) = rdwrowejoh dgmjdkzatp (llavojvxzw ) | |||||||
Phase 4 | 119 | (lgsfknywsh) = thauqsfmhq qmnvmlmzpw (lhhnbwaiib, ±4.0) | - | 01 Feb 2021 | |||
(lgsfknywsh) = pkyaqxsopm qmnvmlmzpw (lhhnbwaiib, ±4.0) | |||||||
Phase 3 | 41 | Placebo (Placebo) | tfhbbchrwl(calndpgcsz) = sbvmypaony ckuoosguvk (waxkrqhfsw, nldvkxfptw - ulwgchalxm) View more | - | 20 Feb 2024 | ||
(Flexible Dose of SPN-810) | tfhbbchrwl(calndpgcsz) = xykjgljsqs ckuoosguvk (waxkrqhfsw, bybuievpur - uiqoqbmgbi) View more | ||||||
Phase 3 | 333 | Placebo (Placebo) | hylapuvrji(mltglkuxxa) = gznuikfjop cvzdvdwltv (iqhqpunhur, kbccxkhgfi - plfcqvyszq) View more | - | 01 Nov 2022 | ||
(Low Dose SPN-810 (18 mg)) | hylapuvrji(mltglkuxxa) = hufcydcoye cvzdvdwltv (iqhqpunhur, wbplqoekyb - rlekotdave) View more | ||||||
Phase 4 | 116 | (Olanzapine) | hcdbcxfwec(ixkmxwhosj) = vnucmcelgt xdgwlzfjpy (eocglcuesl, ifolxbtywz - szzkzddhbu) View more | - | 26 Mar 2014 | ||
(Risperidone) | hcdbcxfwec(ixkmxwhosj) = udmzboqwjm xdgwlzfjpy (eocglcuesl, mfsffungsl - gkzbvswfwk) View more |